Results 121 to 130 of about 35,468 (143)
Some of the next articles are maybe not open access.
Vaccination of Infants With HPV-77 Vaccine
Archives of Pediatrics & Adolescent Medicine, 1969IN 1966, clinical trials demonstrated that a rubella virus modified by 77 passages in African green monkey kidney cultures (GMK) was attenuated for man. 1,2 This strain (HPV-77) produced asymptomatic immunizing infections that were not communicable to contacts. The HPV-77 could be recovered from the respiratory secretions of recipients, and the vaccine
Pavilanis, Vytautas +3 more
openaire +2 more sources
Asia-Pacific Journal of Clinical Oncology, 2011
AbstractAims: The primary prevention for cervical cancer, a human papilloma virus (HPV) vaccine, has been available in Thailand for almost 3 years. The present study evaluates knowledge about the Papanicolaou (Pap) smear, HPV and the HPV vaccine and focuses on identifying predictors for the acceptability of the HPV vaccine.Methods: A sample of 764 ...
Chuenkamon, Charakorn +5 more
openaire +2 more sources
AbstractAims: The primary prevention for cervical cancer, a human papilloma virus (HPV) vaccine, has been available in Thailand for almost 3 years. The present study evaluates knowledge about the Papanicolaou (Pap) smear, HPV and the HPV vaccine and focuses on identifying predictors for the acceptability of the HPV vaccine.Methods: A sample of 764 ...
Chuenkamon, Charakorn +5 more
openaire +2 more sources
BMJ, 2015
After nine years of experience, the picture remains reassuring Prophylactic vaccines against human papillomavirus (HPV) were first licensed for use in girls and young women in 2006, with more than 175 million doses distributed worldwide by 2013.1 Bivalent and quadrivalent vaccines protect against new infection with oncogenic HPV types 16 and 18 ...
openaire +2 more sources
After nine years of experience, the picture remains reassuring Prophylactic vaccines against human papillomavirus (HPV) were first licensed for use in girls and young women in 2006, with more than 175 million doses distributed worldwide by 2013.1 Bivalent and quadrivalent vaccines protect against new infection with oncogenic HPV types 16 and 18 ...
openaire +2 more sources
HPV vaccines: State of the art
Journal of Cellular Physiology, 2010AbstractCervical cancer is one of the most common types of cancer in women worldwide and is frequent in relatively young women. In the last decades, its incidence has decreased following the implementation of screening programs, mainly in developed countries.
D'Andrilli G +2 more
openaire +5 more sources
Pediatric Annals, 2019
Human papillomavirus (HPV), the most common sexually transmitted viral infection worldwide, is the causative agent for cervical cancer and attributed to anogenital cancers as well as oropharyngeal cancer. Three effective, safe, prophylactic HPV vaccines have been licensed, and studies have demonstrated decreases in HPV prevalence and HPV ...
openaire +2 more sources
Human papillomavirus (HPV), the most common sexually transmitted viral infection worldwide, is the causative agent for cervical cancer and attributed to anogenital cancers as well as oropharyngeal cancer. Three effective, safe, prophylactic HPV vaccines have been licensed, and studies have demonstrated decreases in HPV prevalence and HPV ...
openaire +2 more sources
BMJ, 2011
Most deaths from cervical cancer occur in countries without the resources to screen, treat, or vaccinate against the disease.
openaire +2 more sources
Most deaths from cervical cancer occur in countries without the resources to screen, treat, or vaccinate against the disease.
openaire +2 more sources
International Journal of Gynecology & Obstetrics, 2006
AbstractVaccines to prevent infection with high‐risk human papillomaviruses (HPV) will help protect women against cervical cancer, and some are likely to be available within the next year. One vaccine, a quadrivalent vaccine against HPV types 6, 11, 16 and 18 and known as Garadsil ©(Merck &Co., Inc), was approved by the Federal Drug Administration (
openaire +5 more sources
AbstractVaccines to prevent infection with high‐risk human papillomaviruses (HPV) will help protect women against cervical cancer, and some are likely to be available within the next year. One vaccine, a quadrivalent vaccine against HPV types 6, 11, 16 and 18 and known as Garadsil ©(Merck &Co., Inc), was approved by the Federal Drug Administration (
openaire +5 more sources